Buscar
Mostrando ítems 11-20 de 22
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Examining the immune signatures of SARS-CoV-2 infection in pregnancy and the impact on neurodevelopment: protocol of the SIGNATURE longitudinal study
(FRONTIERS MEDIA SA, 2022)
The COVID-19 pandemic represents a valuable opportunity to carry out cohort studies that allow us to advance our knowledge on pathophysiological mechanisms of neuropsychiatric diseases. One of these opportunities is ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders
(Elsevier, 2022)
Abstract Background Sex differences in incidence and/or presentation of schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BIP) are pervasive. Previous evidence for shared genetic risk and sex ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs
(WILEY, 2022)
The Enhancing NeuroImaging Genetics through Meta-Analysis copy number variant (ENIGMA-CNV) and 22q11.2 Deletion Syndrome Working Groups (22q-ENIGMA WGs) were created to gain insight into the involvement of genetic factors ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis
(Oxford University Press, 2022-05-31)
Objective Aripiprazole and risperidone are 2 of the most used second-generation antipsychotics (SGAs) worldwide. Previous evidence shows a similar effect of these SGAs on weight and metabolic changes in the short term. ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Routine cerebrospinal fluid parameters as biomarkers in first-episode psychosis: A prospective observational study
(PERGAMON-ELSEVIER SCIENCE LTD, 2022)
In recent years, multiple studies have investigated the role of biomarkers in first-episode psychosis (FEP) to facilitate early diagnosis, disease stratification, therapeutic choice and outcome prediction. Few studies ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: a 1-year follow-up study
(Elsevier, 2022)
Background Neurocognition impairments are critical factors in patients with major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ), and also in those with somatic diseases such as type 2 diabetes ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Interaction testing and polygenic risk scoring to estimate the association of common genetic variants with treatment resistance in schizophrenia
(American Medical Association, 2022)
Importance About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders
(Blackwell Publishing Inc., 2022)
Objective: Obesity and metabolic diseases such as metabolic syndrome (MetS) are more prevalent in people with type 2 diabetes mellitus (T2DM), major depres sive disorder (MDD), bipolar disorder (BD), and schizophrenia ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium
(Elsevier, 2022-10-12)
Introduction Our aim was to, firstly, identify characteristics at first-episode of psychosis that are associated with later antipsychotic treatment resistance (TR) and, secondly, to develop a parsimonious prediction model ...
Artículo
![Con acceso al texto completo Icon](/themes/idUS//images/acceso/opened_access.png)
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples
(Elsevier, 2022-08-19)
Background Cardiometabolic dysfunction is common in young people with psychosis. Recently, the Psychosis Metabolic Risk Calculator (PsyMetRiC) was developed and externally validated in the UK, predicting up-to six-year ...